Abstract: The present disclosure provides a canine parvovirus (CPV) nanobody CPV-VHH-H1 and use thereof, belonging to the technical field of immunology. A heavy-chain variable region sequence of the nanobody CPV-VHH-H1 has the amino acid sequence set forth in SEQ ID NO: 1; and a gene encoding the nanobody CPV-VPP-H1 has the nucleotide sequence set forth in SEQ ID NO: 2. In the present disclosure, a nanobody immune library of the CPV is constructed by a phage display technology, a specific anti-CPV nanobody CPV-VHH-H1 is obtained by screening, and it is verified by experiments that the nanobody may specifically bind to the CPV. The present disclosure is expected to develop a new nanobody preparation for use in clinical diagnosis and treatment of the CPV, and provides a certain theoretical reserve for applying the nanobody to the field of veterinary biological products.

Abstract: The present invention provides diagnostic markers for Bovine tuberculosis and uses thereof. In the present invention, markers capable of differentiating Bovine tuberculosis negative or positive are obtained by screening with untargeted proteomic techniques and verifying with targeted proteomic techniques, which are IL-8, CRP. The diagnostic markers for Bovine tuberculosis provided in the present invention can identify whether the cattles to test are Bovine tuberculosis negative or positive, and whether positive tuberculosis cattles are at discharge period of bacteria. The diagnostic markers can be used in the preparation of kits or reagents for detecting Bovine tuberculosis, thus providing new detection targets for the diagnosis of Bovine tuberculosis, which is helpful to the prompt detection and elimination of tuberculosis cattles, also ensuring the comprehensive prevention and control of Bovine tuberculosis.